The role of bisphosphonates in the treatment of postmenopausal osteoporosis
postmenopausal women have an increased risk of developing osteoporosis. Estrogen deficiency causes an increase in the activity of osteoclastic resorption without a corresponding increase in the activity of osteoblasts, which ultimately leads to a violation of the bone structure. About 200 million women worldwide are affected by osteoporosis; every third woman over 50 suffers an osteoporotic fracture. The risk of developing osteoporosis and fractures varies depending on ethnicity, so black women have a lower risk compared to fair-skinned women, while Spanish and Asian women have a higher risk of osteoporosis, but a similar or lower risk of fractures. Bisphosphonates are one of the most commonly used anti-osteoporosis drugs, acting on osteoclasts, they inhibit bone resorption, thereby minimizing the risk of fractures. This literature review discusses the main methods of treatment of postmenopausal osteoporosis, the most attention is paid to assessing the effectiveness of the use of bisphosphonates.